Primate growth hormone (GH) has evolved rapidly, having undergone ϳ30% amino acid substitutions from the inferred ancestral eutherian sequence. Nevertheless, human growth hormone (hGH) is physiologically effective when administered to nonprimate mammals. In contrast, its functional counterpart, the human growth hormone receptor (hGHR), has evolved species specificity so that it responds only to Old World primate GHs. It has been proposed that this species specificity of the hGHR is largely caused by the Leu → Arg change at position 43 after a prior His → Asp change at position 171 of the GH. Sequence analyses supported this hypothesis and revealed that the transitional phase in the GH:GHR coevolution still persists in New World monkeys. For example, although the GH of the squirrel monkey has the His → Asp substitution at position 171, residue 43 of its GHR is a Leu, the nonprimate residue. If the squirrel monkey truly represents an intermediate stage of GH:GHR coevolution, its GHR should respond to both hGH and nonprimate GH. Also, if the emergence of species specificity was a result of the selection for a more efficient GH:GHR interaction, then changing residue 43 of the squirrel monkey growth hormone receptor (smGHR) to Arg should increase its binding affinity toward higher primate GH. To test these hypotheses, we performed protein-binding assays between the smGHR and both human and rat GHs, using the surface plasmon resonance methodology. Furthermore, the effects of reciprocal mutations at position 43 of human and squirrel monkey GHRs are measured for their binding affinities toward human and squirrel monkey GHs. The results from the binding kinetic assays clearly demonstrate that the smGHR is in the intermediate state of the evolution of species specificity. Interestingly, the altered residue Arg at position 43 of the smGHR does not lead to an increased binding affinity. The implications of these results on the evolution of the GH:GHR interaction and on functional evolution are discussed.
Introduction
The mammalian pituitary growth hormone (GH) has been studied extensively in various disciplines of biological research (Wells 1994; Kossiakoff 1995; Li 1997, p. 180; Liu et al. 2001) . Much information has come from studying the interaction of the human growth hormone (hGH) with the extracellular domain (ECD) of the human growth hormone receptor (hGHR) (also called the GH-binding protein but referred to as GHR-ECD in this report), which is found freely circulating in serum and is able to bind hGH with the same affinity as does the full-length receptor (Fuh et al. 1990 ). The biologically active ternary complex is formed from one GH molecule and two GHRs through a sequential process of high-affinity site 1 binding followed by site 2 binding (De Vos, Ultsch, and Kossiakoff 1992; Wells 1994) .
The GH and the GHR also provide an opportunity to understand the coevolution of two proteins. Wallis (1994) compiled the evolutionary rates of GHs from various mammalian taxa to show that, in general, GH evolves at a slow basal rate, but significant acceleration in evolutionary rate occurred in two lineages, one leading to the primates (human and Rhesus monkey) and the other to the artiodactyls (Wallis 1994) . The acceleration seen in the primate lineage is exceptionally high (Li 1997) . It has been proposed that positive selection may be a driving force for the observed acceleration (Wallis 1996; Liu et al. 2001; Wallis, Zhang, and Wallis 2001) . The acceleration was particularly conspicuous at ''functionally important'' sites (Liu et al. 2001) , which were inferred from functional epitope mapping of the hGH·(hGHR-ECD) 2 complex , 1991 , 1993 , as well as the tertiary structure of the hGH and human prolactin receptor complex (Somers et al. 1994) .
Among these functionally important sites, one pair of residues is of particular interest with regard to the origin of species specificity of the hGHR. In general, protein hormones from nonprimates are active in humans. However, human and Rhesus monkey GHRs are unresponsive to GHs from nonprimate mammals (Carr and Friesen 1976; Peterson and Brooks 2000) . In contrast, the hGH is fully functional when administered to other mammalian species. This pattern of high specificity and cross-reactivity is not well understood at either the biochemical or the evolutionary level. On the basis of the sequence comparisons, Souza et al. (1995) proposed that the interaction between residue 171 of the GH (GH171Asp in human, which is equivalent to GH170His in nonprimates) and residue 43 of the GHR (GHR43Arg in human and GHR43Leu in nonprimates) is the major determinant of the hGHR species specificity. At the hGH:hGHR site 1 interface, GH171Asp and GHR43Arg are known to form a strong salt bridge and are, therefore, assumed to be essential for the formation of the hormone-receptor complex (De Vos, Ultsch, and Kossiakoff 1992; see fig. 1 ). Among the residues that are known to form favorable salt bridges and hydrogen bonds at the site 1 interface, these two are the only pair of structurally complementary residues that differ at (De Vos, Ultsch, and Kossiakoff 1992) are shown in italic, with the complementary residues in superscript. The structurally complementary residues GH171 and GHR43 are shown in bold. The rest of the table represents the residues comprising the interface for site 1 binding as shown by alanine-scanning mutageneses of hGH and hGHR , 1991 , 1993 Clackson and Wells 1995; Clackson et al. 1998). both positions between primates and nonprimates (see table 1 ).
Evolutionary analyses of GH and GHR sequences from simians and prosimians showed that the substitution GH171His → GH171Asp occurred in the lineage leading to the common ancestor of Platyrrhines and Catarrhines (Liu et al. 2001; Wallis, Zhang, and Wallis 2001) , followed by the substitution GHR43Leu → GHR43Arg in the common ancestor of the Old World monkeys (Liu et al. 2001) . Notably, Liu et al. (2001) reported the presence of an ''intermediate'' stage; the two New World monkey species studied, the squirrel monkey and the spider monkey, possess the primatetype GH (Asp171), whereas their GHRs still have the nonprimate-type Leu at residue 43. If the compatibility between GH171 and GHR43 is truly a major determinant of the binding specificity, then the GHR of the New World monkey species represents a functionally intermediary status. Therefore, GHRs from these species should bind to both primate and nonprimate GHs. They also provide a chance to examine whether a functionally intermediate stage of evolution reflects an intermediate stage of natural selection, in other words, whether the GHR43Leu → GHR43Arg substitution has any selective advantage, i.e., if the evolution of the hGHR species specificity was a result of positive selection.
In this study we investigated the range of binding affinities of squirrel monkey growth hormone receptor (smGHR) by conducting in vitro binding assays between the squirrel monkey growth hormone receptor ECD (smGHR-ECD) and the GHs from human, squirrel monkey, and rat (a nonprimate outgroup). The surface plasmon resonance (SPR) measurement technique was used to measure the kinetic rate constants and the corresponding binding affinities. Our study suggests that the smGHR-ECD does represent an intermediary form of species specificity. To further test whether this is caused by the compatible interaction between GH171 (GH170 in nonprimates) and GHR43, we engineered and produced human and squirrel monkey GHR-ECDs with converse amino acids at residue 43. By this, we were able to alter smGHR-ECD to acquire species specificity, whereas hGHR-ECD with Leu at position 43 gained an affinity toward rat GH, thereby losing its species specificity. In contrast to these significant effects of mutations at residue 43 of primate GHRs on the interactions with the nonprimate GH, the same mutations have very little effect on the binding affinities toward primate GHs. This demonstrates an example of a single mutation in a protein hormone that has very different functional consequences on its interactions with receptors from distinct phylogenetic groups.
Materials and Methods

Oligonucleotide-Directed Mutagenesis
The cDNA clones for the squirrel monkey (Saimiri boliviensis) growth hormone (smGH) and the smGHR-ECD were obtained from a previous study (Liu et al. 2001) . Mutations were introduced via oligonucleotidedirected mutagenesis (Kunkel, Roberts, and Zakour 1987) single-stranded DNA produced using M13-VCS helper phage from Stratagene (La Jolla, Calif.). Custom oligonucleotides carrying the designed mutation were purchased from Integrated DNA Technologies Inc. (Coralville, Iowa). Following Clackson et al. (1998) , truncated forms of GHR-ECDs (amino acid residues 29-238) were expressed and isolated for binding studies. A Ser237Cys mutation was introduced into GHR-ECDs so that the constructs could be attached to the biosensor chip (see Biosensor Surface Preparation for more detail). All mutations were confirmed at the nucleotide level by sequencing on an ABI 377 sequencer. The oligonucleotide sequences used to introduce mutations are shown in table 2.
Construction of Expression Plasmids
The expression vector used for this study was from Genentech Inc. (South San Francisco, Calif.) (Fuh et al. 1990 ). All constructs discussed in this report were made using the phGHr expression plasmid (Fuh et al. 1990 ). NsiI and NotI restriction sites were added to the 5Ј and 3Ј ends of each insert by PCR. The PCR primers used are shown in table 2. At least eight single colonies per construct were picked and analyzed for their plasmids by sequencing the entire inserts. For general cloning purpose, the JM109 strain of E. coli from Invitrogen (Carlsbud, Calif.) was used. For expression, the proteinase-deficient BL21 strain of E. coli from Stratagene was used.
Expression and Purification of Periplasmic Proteins
BL21 cells were transformed with each expression plasmid. From the resulting plates, a single colony was picked and inoculated in the Luria-Bertani media containing 60 g/ml ampicillin in 1/100th volume of the final culture. The cells were grown for 4 h at 37ЊC, then washed with and transferred into a larger volume of lowphosphate AP-5 media to induce the alkaline phosphatase promoter-directed transcription of the recombinant proteins (Fuh et al. 1990 ). The optimized growth conditions for all the GHR-ECD variants are at 20ЊC for 28 h, with shaking at 225 rpm. Expression plasmid for smGH was grown at 32ЊC for 11 h. Cells were then harvested to be frozen at Ϫ80ЊC. Periplasmic proteins were extracted through repeated freezing-thawing steps in 1/100 volume of the original culture of 10 mM TrisCl (pH 8.0). Whether the protein of expected size was present or not in the periplasmic protein fraction was checked from this stage by SDS polyacrylamide gel electrophoresis (PAGE) or by Western blotting (or both), using the anti-hGH (catalog number E45600M, BioDesign International, Kennebunk, Me.) for GHs and MAb against hGHR (product number 7005B, American Diagnostica Inc., Greenwich, Conn.). The supernatant was then ammonium sulfate precipitated to be resuspended into 3 ml of 10 mM Tris-HCl, pH 8.0, buffer and then further processed according to the different purification procedures discussed subsequently.
Fast Protein Liquid Chromatography Purification of hGH
The ammonium sulfate-precipitated periplasmic protein fraction containing hGH was desalted on a PD-10 column (Amersham Pharmacia Biotechnology, Piscataway, NJ) and applied onto a Resource Q column (Amersham Pharmacia Biotechnology) equilibrated with 10 mM Tris-Cl (pH 8.0). The hormone was then eluted by a 0-to 300-mM NaCl gradient using a Fast Protein Liquid Chromatography apparatus (Varian Prostar model 210). The resulting fractions were concentrated on a Centricon 10k filtering unit (Amicon) and analyzed on SDS-PAGE, reverse-phase HPLC (Shimadzu LC10AD VP system with a Vydac Protein C4 column), and mass spectrometry (PE Sciex API 150Ex). The concentrations of all samples were determined by absorbance at 280 nm. Extinction coefficients were derived from the tryptophan and tyrosine content (for example, 280 
Affinity Chromatography for the Isolations of GHR-ECDs
Each ammonium sulfate-precipitated periplasmic protein fraction containing GHR-ECD was applied to a hGH affinity column (Fuh et al. 1990 ), which was washed and equilibrated in 20 mM Tris-HCl, pH 8.0. The 2-ml column was then washed with the same buffer containing 10 mM MgCl 2 and finally with 1.0 M NaCl. The specifically bound proteins were then eluted with 2.5 ml 4.5 M MgCl 2 . The eluted proteins were immediately desalted on a PD-10 column (Amersham Pharmacia Biotechnology) in 10 mM sodium phosphate buffer, pH 7.4, and then further analyzed as described above.
Affinity Chromatography for smGH Isolation
To purify smGH, an smGHR-ECD affinity column was constructed. First, ϳ5 mg of smGHR-ECD237Cys from a 10-liter culture was purified using an hGH affinity column. Because this GHR-ECD contained 237Cys mutation, it was glutathione modified on the unpaired cysteine by E. coli. After removing the glutathione modification to free the thiol residue (see Biosensor Surface Preparation for the detailed protocol), the purified smGHR-ECD was biotinylated using the EZ-Link PEO-Maleimide-activated biotin (Pierce, Rockford, Ill.) and then coupled to immobilized streptavidin-containing beads (UltraLink immobilized streptavidin plus, Pierce). We were able to obtain Ͼ95% pure smGH using this column. Preliminary binding experiments with hGHR-ECD using the pure smGH obtained from this column led to an observation that the smGH binds to hGHR-ECD with high affinity. After this, we constructed a higher-capacity hGHR-ECD affinity column for the purification of a larger amount of smGH, using Ͼ15 mg of hGHR-ECD immobilized through random amine coupling using CNBr-activated Sepharose beads (Amersham Pharmacia Biotechnology). The smGH was then purified following the same affinity column purification steps described earlier and desalted in PBS (pH 7.4).
Preparation of GHR-ECDs for Immobilization
As mentioned earlier, a point mutation Ser237Cys was introduced in the receptor. The Ser237Cys mutation does not affect hormone binding and allowed us to immobilize the GHR-ECDs in a homogeneously oriented manner, using a thiol-disulfide exchange coupling method. In all cases, the extra unpaired cysteine residue on the receptor introduced by this mutation became covalently modified in E. coli by glutathione. This modification was removed by a 30-min treatment in 1 mM dithiothreitol (DTT) on ice for the Ser237Cys mutants of hGHR-ECD and hGHR-ECD43Leu. The Ser237Cys-containing smGHR-ECD and smGHR-ECD43Arg were treated in a milder reducing reagent, 7.5 mM ␤-mercapthoethanolamine for 15 min at 37ЊC in the presence of 50 mM EDTA.
Biosensor Surface Preparation
BIAcore Pioneer C-1 sensor chips were used for the analyses. Reagents for this, N-ethyl-NЈ-(s-dimethylaminopropyl)-carbodiimide hydrochloride (EDC), N-hydrosuccinimide (NHS), and 2-(2-pyridinyldithio) ethaneamine hydrochloride (PDEA), were purchased from Biacore (Uppsala, Sweden). First, the surface of the Pioneer C-1 chip was treated with 15 l of 100 mM Naglycinate and 0.3% Triton-X solution (pH 12.0) and was then equilibrated with degassed HBS buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, 0.005% Tween 20, pH 7.4). Then, the surface carboxyl groups were activated with a 0.05 M NHS-0.2 M EDC solution. Activated thiol groups were introduced by a 40-l injection of 80 mM PDEA (in 0.1 M sodium carbonate buffer pH 8.5). This step was followed by manual injection of the Ser237Cys-containing GHR-ECDs of 0.1-mg/ml concentration in 10 mM sodium acetate pH 4.5 buffer. The excess reactive thiol compound was quenched by a 30-l injection of 50 mM glutathione. The control surface was activated and blocked as mentioned before but had no protein immobilized. The same HBS buffer, as mentioned before, was used for all the measurements with the flow rate of 50 l/min.
SPR Measurements and Analyses of Binding Kinetics Data
A BIAcore2000 measures the refractive index near the sensor surface by SPR (see Fisher et al. 1994 for an application of this technology). We injected twofold serial dilutions of the GH solutions into cuvettes containing the analysis chip. Buffer-only injection representing 0 nM analyte was also included and subtracted from all the sensorgrams in the same set to minimize the noise introduced by the experimental procedure. All measurements were repeated at least four times to ensure reproducibility. On average, two independent measurements from two chips were performed to assess the interactions.
Because of the short and rigid linker of the C-1 chip, the immobilized receptor molecules cannot interact with each other. Thus, GH binding specifically through site 1 can be analyzed without the complication of subsequent interactions through site 2 (Bernat et al., unpublished data). The kinetics of the site 1 GH:GHR-ECD interaction can, therefore, be accurately described by a simple bimolecular or Langmuir interaction:
where k on is the association rate constant and k off the dissociation rate constant. Analyzing the kinetics of the binding interactions, we determined both k on and k off values and ultimately the corresponding equilibrium dissociation constant (
Using the sensorgrams from analytes of different concentrations, a global fit of both association and dissociation rate constants for each interaction was generated. The data were analyzed using the BIA evaluation 3.0 software (Biacore), applying the simple 1:1 (Langmuir) binding model for the fitting.
Results
Expression and Purification
Typical yields for hGH, hGHR-ECD, and hGHRECD43Leu were at 4 mg recombinant protein purified from 1 liter of the culture. Expression of smGH, sm-GHR-ECD, and smGHR-ECD43Arg was much lower, resulting in less than 1 mg purified protein from 1 liter of the culture. After affinity chromatography, the samples were 95% pure, as judged by HPLC analysis. We confirmed the presence of all the desired mutations by measuring the mass differences caused by differently encoded amino acids using mass spectrometry. In the case of smGH, the prolonged time of expression resulted in a mass of 18 units above the theoretical mass, presumably because of an additional water molecule resulting from the cleavage of one of the peptide bonds. The cleaved and intact hormones have practically the same binding characteristics (data not shown). When the cells were grown over 25 h, 100% of the proteins were in cleaved form. Reducing the growth time to less than 12 h successfully prevented this cleavage. Only data for the intact forms were included in this paper.
All Ser237Cys variants were modified by glutathione at the unpaired cysteine residue during the expression. This modification was successfully removed by DTT without affecting the native disulfides of the protein for 237Cys mutants of hGHR-ECD and hGHRECD43Leu. This was not the case for smGHR-ECD and its variant. The same condition turned out to be too harsh for the 237Cys smGHR-ECD variant, leading to reduction of the native disulfide bonds and ultimate denaturation of the protein. Despite the small number of amino acid sequence differences between human and squirrel monkey GHRs, the stability and reactivity of their disulfides are measurably different, suggesting subtle tertiary structure differences. A milder reducing reagent ␤-mercapthoethanolamine was used to empirically determine an optimal treatment condition. A 20-min treatment with 7.5 mM ␤-mercapthoethanolamine solution at 37ЊC with the presence of 50 mM EDTA was effective and safe for the removal of the glutathione modification.
Determination of Binding Kinetics
SPR is a method capable of measuring the binding interactions between molecules by using the changes in refractive index to measure the mass changes of molecules bound to the analysis chip. These changes were reported as ''response units (RUs).'' The RU values are linearly proportional to the amount (mass) of the analytes binding to the ligands. A typical sensorgram is composed of two characteristic phases. In the first (association) phase, the GH is injected above the GHR-ECD-containing surface, allowing the association of the GH to the immobilized GHR-ECD. However, simultaneous dissociation of the GH from the resulting GH: GHR-ECD complex also occurs in this phase. A sufficiently long injection time leads to a steady-state response level characterized by equal rates of association of the GH to GHR-ECD and of dissociation of the GH from the GH:GHR-ECD complex. In the second (dissociation) phase, instead of the GH, only the running buffer is injected. In this phase only the dissociation of the GH from the previously formed GH:GHR-ECD complexes occurs because there is no further supply of GH injected over the surface. Figure 2A shows the sensorgrams generated from the responses of hGHR-ECD237Cys to the three different GHs: hGH, smGH, and rat GH. The interaction between hGH and hGHR-ECD has a K d ϭ 3.5 nM (table  3) . Interestingly, the smGH binds to the hGHR-ECD with approximately the same affinity as hGH does (K d ϭ 3.3 nM). As expected, the rat GH does not bind to the hGHR-ECD. Figure 2B shows the sensorgrams from the binding of smGHR-ECD237Cys to three different hormones. The hGH and the smGH bind to the smGHR-ECD with virtually identical affinities (ϳ2 nM) (table 3). A major difference between hGHR and smGHR lies in their responses to the rat GH. In contrast to the behavior of the hGHR, the smGHR-ECD shows clear binding to the rat GH. The binding affinity of smGHR-ECD to the rat hormone is about 20 times weaker when compared with the interaction between smGHR-ECD and smGH because of the significantly decreased association rate constant value for the interspecies binding interaction (table 3) .
Different Species Specificities of Human and Squirrel Monkey GHR-ECDs
GHR-ECD Residue 43 is a Major Determinant of Species Specificity
As described above, the wild-type hGHR-ECD shows no binding affinity toward the rat GH in accord with the well-established species specificity of Old World primate GHRs. However, introduction of a single mutation Arg43Leu provided binding toward the rat hormone that was only slightly weaker than the wild-type hGHR-ECD:hGH interaction ( fig. 3A and table 3 ), whereas it conserved strong binding to the hGH and the smGH. Moreover, we introduced a converse mutation to smGHR-ECD. The resulting variant smGHR-ECD43Arg (with a human residue at position 43) completely lost its affinity toward rat GH ( fig. 3B and table 3 ), while maintaining its affinity toward hGH and smGH. In other words, it acquired a species specificity to respond only to primate GHs. This strongly suggests that the amino acid at position 43 is likely to be the primary determinant for the so-called species specificity: Arg confers, whereas Leu disables, the species specificity. 
The Effects of Reciprocal Mutations at Residue 43 of the Primate GHR-ECDs
We were able to make comparisons of the binding affinities of interaction between primate GHs and their receptors with regard to position 43 to elucidate the role of residue 43 of the GHR in within-primate interactions (table 3) . The hGH binds tightly to both human and squirrel monkey GHR-ECDs. The interaction between hGH and smGHR-ECD was the strongest among the comparisons. Interestingly, the interactions between hGH and hGHR-ECD43Leu and smGHR-ECD43Arg were kinetically very similar (3.9 nM for both cases; table 3).
The purified smGH binds tightly to both its own receptor and hGHR, with 2.3-and 2.0-nM dissociation constants, respectively (table 3). The binding between smGH and smGHR-ECD with the human residue Arg at position 43 was weaker than the wild-type interactions (5.7-nM compared with 2.3-nM dissociation constant). Binding of smGH toward the mutant hGHR-ECD, encoding residue Leu at positon 43, is about twofold weaker than the binding toward the wild-type hGHR-ECD (6.0-vs. 3.3-nM dissociation constants).
Overall, there is no directional effect of residue 43 on the within-species binding affinities observed. Therefore, in contrast to the dramatic effect of residue 43 on the binding toward the rat GH, within human and squirrel monkey GHRs, whether residue 43 is Leu or Arg does not affect the binding affinities in the same direction. For both species, the binding affinities were greater for the wild-type interactions. At the same time the wildtype interactions were not the strongest; we observed Binding affinity relative to WT is in comparison with the interactions between wild-type GHR-ECD and the corresponding GH, i.e., between hGHR-ECD and hGH interaction for the cases involving hGHR-ECD and hGHR-ECD43Leu, and between smGHR-ECD and smGH interaction for the cases involving smGHR-ECD and smGHR-ECD43Arg. the strongest binding interactions between hGH and smGHR-ECD. Although hGH showed similar binding affinity across the various GHR-ECDs used, smGH showed more variation in terms of binding affinity toward different GHR-ECDs.
Discussion
Effects of Mutations on the Binding Kinetics and Difficulties of Deciphering Protein Evolution from Simple Binding Data
Except for the rat GH:smGHR-ECD interaction, the observed association rates for all the binding assays conducted in this study were similar (table 3). In the case of rat GH:smGHR-ECD, it was the association rate that was more than an order of magnitude lower than those from other types of interactions assessed. The cause for this is unknown; without the knowledge of the threedimensional structure of the rat GH and the smGHR-ECD, we cannot infer the conformational changes involved in the complex formation. The low association rate also lowered the resolution of the measurements, resulting in a large random error for this specific interaction. In contrast to this, rat GH binds to hGHRECD43Leu with an association rate similar to that of primate GHs. Interestingly, the dissociation rate constant values were similarly low for all the GH:GHR-ECD complexes studied. The fact that both hGH and smGH tend to bind weaker to mutant GHR-ECDs suggests that the mutation at residue 43 slightly disturbs the wild-type GHR-ECD structure. In other words, the smGHRECD43Arg is a close, but not perfect, substitute for hGHR-ECD, and the same is true for the other mutant GH-wild-type GHR pair. Other nearby differences of residue conformations in the three-dimensional structures might cause such an effect.
Inferring the selective advantage or disadvantage of a specific amino acid substitution by means of functional data is not straightforward. For example, the effects of mutations may not be additive, but synergistic. Indeed, Clackson et al. (1998) reported that some of the mutations outside the structural epitopes of hGHR could indirectly influence the binding affinity. Therefore, inferring the significance of individual residues serves as only the first step in understanding the phenotypic consequences of specific substitutions. Another limitation of the measurement of choice presented in this report lies in the fact that the present study focused only on the interaction between GHR-ECDs and GHs through site 1 binding. It should be noted that the species specificity was originally described in a biological system (Carr and Friesen 1976) in which both site 1 and site 2 interactions occur. The site 1 binding affinity accounts for the first step of the cascade of the biological signal transduction pathway (Kossiakoff 1995) . It is possible that the kinetics of site 1 and site 2 binding may behave differently in response to a single mutation. Unfortunately, this aspect of GH:GHR interactions has not been investigated in detail yet because of the fact that it is technically challenging to measure the site 1 and site 2 binding affinities separately. A new SPR technique for this purpose, however, has been developed recently (Bernat et al., unpublished data) . Determining whether the effect of a mutation that is critical in site 1 binding affinity, such as the GH171 or GHR43 residue, has the same degree of significance at the site 2 binding affinity will be important to elucidate the underlying biological consequences and to facilitate the understanding of the trajectories of functional evolution.
Origin and the Evolution of the Major Determinant of Old World Primate GHR Specificity
The species specificity of the Old World primate GHR is an example of the dramatic functional differences of the same proteins from different phylogenetic units. Although most of the hormones produced in one mammalian species are physiologically effective when injected into another species, the incompatibility of human and Rhesus monkey GHRs toward nonprimate GHs stands out as a notable exception (Carr and Friesen 1976) .
Efforts to elucidate the molecular basis of species specificity became successful only after detailed structural and biochemical knowledge of the GH and GHR interaction became available. A high-resolution X-ray structure of the ternary hGH·(hGHR-ECD) 2 complex (De Vos, Ultsch, and Kossiakoff 1992) revealed the amino acid residues that are directly involved in the formation of the ternary complex (table 1) . Complementary binding studies using systematic mutagenesis strategies both on the hormone ) and on the receptor (Clackson and Wells 1995; Clackson et al. 1998 ) identified the most important residues for the site 1 interaction (table  1) . On the basis of this information, it was speculated that the structurally complementary residues Asp171 of the hormone and Arg43 of the receptor were the principal determinants of species specificity (Souza et al. 1995) .
Recently, Liu et al. (2001) and Wallis, Zhang, and Wallis (2001) studied three New World monkey species, i.e., squirrel monkey, spider monkey, and marmoset, and the light of this conclusion, it will be of great interest to investigate whether the GH171His → GH171Asp change had any significant selective advantage. This substitution provided the biochemical basis for the emergence of the species specificity of Old World primate GHRs. Interestingly, the timing of this substitution coincides with the acceleration in the evolutionary rate observed in the ancestral lineage leading to higher primates (Liu et al. 2001) .
